何锋，研究员，上海中医药大学中西医结合研究院

博士毕业于美国University of Oklahoma Health Sciences Center，主要从事酒精性、非酒精性脂肪肝，毒物引发的脂肪肝、肝炎、肝硬化和肝癌的发病机制研究及肿瘤的免疫治疗研究。现主要研究细胞应急反应对机体免疫和代谢平衡的调节及其在肝炎和肝癌发生发展中的作用，以及寻找肝炎和肝癌预防，诊断和治疗的新方法。

获得Eli Lilly的科研创新奖以及Joy Cappel青年研究员奖，承担Eli Lilly的非酒精性脂肪肝炎和肝癌研究基金，参与美国美国国立卫生研究院科学基金5项。

在Cancer Cell, J Hepatol, Proc Natl Acad Sci USA, EMBO J，J Biol Chem., Int J Mol Sci., Carcinogenesis等国外刊物发表SCI论文20多篇，论文平均单篇引用超过70余次，其中第一作者或通讯作者文章单篇最高影响因子20.6。

Feng He, Investigator

Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine

Dr. He obtained his Ph.D. degree from the University of Oklahoma Health Sciences Center, USA. He studied the Alcoholic and Non-Alcoholic Fatty Liver Disease (AFLD/NAFLD), Toxicant-Associated Fatty Liver Disease (TAFLD) and their progression into steatohepatitis, liver cirrhosis and liver cancer as well as tumor immunotherapy. Currently, his research focuses on stress response signaling in the regulation of inflammation and metabolism, and their roles in pathogenesis of cancer as well as exploring the new methods for cancer prevention, diagnosis, and treatment.

Dr. He has received Lilly Innovative Fellowship Award from Eli Lilly and Joy Cappel Young Investigator Award. As a principle investigator, he undertook Eli Lilly’s non-alcoholic steatohepatitis and liver cancer research fund and also participated in 5 research funds from the National Institutes of Health.

Dr. He has published more than 20 research papers in journals such as Cancer Cell, J Hepatol, Proc Natl Acad Sci USA, EMBO J, J Biol Chem., Int J Mol Sci., Carcinogenesis, etc., with an average of more than 70 citations per paper. The highest impact factor of the journals, in which he is a first author or corresponding author, is 20.6.